{"created":"2023-06-20T15:49:14.067051+00:00","id":3808,"links":{},"metadata":{"_buckets":{"deposit":"0eb57c33-83f4-4c33-b036-fefc7bdbafe3"},"_deposit":{"created_by":4,"id":"3808","owners":[4],"pid":{"revision_id":0,"type":"depid","value":"3808"},"status":"published"},"_oai":{"id":"oai:hama-med.repo.nii.ac.jp:00003808","sets":["1:11"]},"author_link":["11379","11377","11378","11376"],"item_3_alternative_title_1":{"attribute_name":"その他のタイトル","attribute_value_mlt":[{"subitem_alternative_title":"Efficacy of VAMP chemotherapy without radiotherapy for stage I Hodgkin lymphoma"}]},"item_3_biblio_info_5":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2020","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"1","bibliographicPageEnd":"32","bibliographicPageStart":"28","bibliographicVolumeNumber":"57","bibliographic_titles":[{"bibliographic_title":"日本小児血液・がん学会雑誌"},{"bibliographic_title":"The Japanese Journal of Pediatric Hematology/Oncology","bibliographic_titleLang":"en"}]}]},"item_3_description_9":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"病期I，病期II A かつ巨大腫瘤を有しない小児の早期ホジキンリンパ腫（HL; Hodgkin lymphoma）に対する標準治療は，2–4コースの多剤併用化学療法と初発時に腫瘍が存在したリンパ節領域（IF; involved field）に対する低線量照射（IF照射）である．早期HLに対し，さまざまな化学療法が試みられている．また，晩期合併症の軽減を目的として，治療反応が良好だった場合，IF照射省略が試みられている．我々は2例の小児早期HLに対して，vinblastine，doxorubicin，methotrexate，prednisoloneによるVAMP療法を実施した．VAMP療法2コース後に18F-fluorodeoxyglucose positron emission tomography/com puted tomography で完全寛解に到達したことを確認し，2コースのVAMP療法を追加してIF照射を省略した．肝酵素上昇と好中球減少症が治療中に認められた有害事象であった．2例は4年以上完全寛解を維持しており，晩期合併症を認めていない．VAMP療法は小児早期HLに対して安全な化学療法レジメンである可能性が示唆された．","subitem_description_type":"Abstract"},{"subitem_description":"The standard treatment for early-stage Hodgkin lymphoma (ESHL), either stage I or IIA without a bulky mass, comprises two to four courses of chemotherapy and involved-field radiation therapy (IFRT). To date, various chemotherapeutic regimens have been attempted for ESHL. In addition, omitting IFRT has been attempted to reduce late effects when a good treatment response is observed. We treated two pediatric ESHL patients with the VAMP regimen comprising vinblastine, doxorubicin, methotrexate, and prednisolone. Both patients achieved complete remission (CR), as confirmed by 18F-fluorodeoxyglucose positron emission tomography/computed tomography, after two courses of the VAMP regimen, followed by two additional courses of the VAMP regimen without IFRT. Elevation of the levels of liver enzymes and neutropenia were the adverse events observed during treatment. Both patients maintained CR and did not develop late effects for more than four years after treatment. The findings of this study suggest that the VAMP regimen is safe for pediatric ESHL.","subitem_description_type":"Abstract"}]},"item_3_publisher_6":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"日本小児血液・がん学会"},{"subitem_publisher":"The Japanese Society of Pediatric Hematology/Oncology"}]},"item_3_relation_27":{"attribute_name":"医中誌論文ID","attribute_value_mlt":[{"subitem_relation_type":"isIdenticalTo","subitem_relation_type_id":{"subitem_relation_type_id_text":"2020326511","subitem_relation_type_select":"ICHUSHI"}}]},"item_3_relation_28":{"attribute_name":"出版社DOI","attribute_value_mlt":[{"subitem_relation_type":"isIdenticalTo","subitem_relation_type_id":{"subitem_relation_type_id_text":"10.11412/jspho.57.28","subitem_relation_type_select":"DOI"}}]},"item_3_rights_7":{"attribute_name":"権利","attribute_value_mlt":[{"subitem_rights":"©2020 日本小児血液・がん学会の許諾を得て掲載"}]},"item_3_source_id_19":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"2187-011X","subitem_source_identifier_type":"ISSN"}]},"item_3_source_id_20":{"attribute_name":"EISSN","attribute_value_mlt":[{"subitem_source_identifier":"2189-5384","subitem_source_identifier_type":"ISSN"}]},"item_3_version_type_32":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"坂口, 公祥"}],"nameIdentifiers":[{"nameIdentifier":"11376","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"川上, 領太"}],"nameIdentifiers":[{"nameIdentifier":"11377","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"小松, 和幸"}],"nameIdentifiers":[{"nameIdentifier":"11378","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"清水, 大輔"}],"nameIdentifiers":[{"nameIdentifier":"11379","nameIdentifierScheme":"WEKO"}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2021-12-20"}],"displaytype":"detail","filename":"日小児血がん会誌-57-28.pdf","filesize":[{"value":"2.0 MB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"日小児血がん会誌-57-28.pdf","url":"https://hama-med.repo.nii.ac.jp/record/3808/files/日小児血がん会誌-57-28.pdf"},"version_id":"753907d3-b119-4aa2-8650-a0d9fb7000af"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"ビンブラスチン","subitem_subject_scheme":"Other"},{"subitem_subject":"ドキソルビシン","subitem_subject_scheme":"Other"},{"subitem_subject":"メトトレキサート","subitem_subject_scheme":"Other"},{"subitem_subject":"プレドニゾロン","subitem_subject_scheme":"Other"},{"subitem_subject":"早期ホジキンリンパ腫","subitem_subject_scheme":"Other"},{"subitem_subject":"vinblastine","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"doxorubicin","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"methotrexate","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"prednisolone","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"early-stage Hodgkin lymphoma","subitem_subject_language":"en","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"病期Iホジキンリンパ腫に対する放射線療法を省略したVAMP療法の有用性","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"病期Iホジキンリンパ腫に対する放射線療法を省略したVAMP療法の有用性"}]},"item_type_id":"3","owner":"4","path":["11"],"pubdate":{"attribute_name":"公開日","attribute_value":"2021-12-20"},"publish_date":"2021-12-20","publish_status":"0","recid":"3808","relation_version_is_last":true,"title":["病期Iホジキンリンパ腫に対する放射線療法を省略したVAMP療法の有用性"],"weko_creator_id":"4","weko_shared_id":-1},"updated":"2023-06-20T16:24:23.064896+00:00"}